Ascendis Pharma (ASND) — insider trading
Health Care
Ascendis Pharma (ASND) has 16 reported SEC Form 4 insider transactions in our data, including 9 open-market purchases and 3 open-market sales among the most recent 16 (latest 2026-09-08).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Bodenhoff Mads | Officer (SVP & PAO) | Option exercise / conversion (derivative) | 3,000 | — | $0 | Form 4 |
| 2026-09-08 | Bodenhoff Mads | Officer (SVP & PAO) | Open-market sale | 3,000 | $270.19 | $810.6K | Form 4 |
| 2026-09-08 | Bodenhoff Mads | Officer (SVP & PAO) | Option exercise / conversion | 3,000 | $110.00 | $330.0K | Form 4 |
| 2026-09-02 | HOLTUG LARS | Director | Open-market sale | 236 | $264.13 | $62.3K | Form 4 |
| 2026-08-14 | BIENAIME JEAN JACQUES | Director | Open-market purchase | 900 | $246.91 | $222.2K | Form 4 |
| 2026-08-14 | BIENAIME JEAN JACQUES | Director | Open-market purchase | 1,100 | $245.85 | $270.4K | Form 4 |
| 2026-06-02 | SMITH SCOTT THOMAS | Officer (EVP & Chief Financial Officer) | Open-market purchase | 100 | $219.00 | $21.9K | Form 4 |
| 2026-05-29 | SMITH SCOTT THOMAS | Officer (EVP & Chief Financial Officer) | Open-market purchase | 250 | $223.32 | $55.8K | Form 4 |
| 2026-05-29 | BIENAIME JEAN JACQUES | Director | Open-market purchase | 100 | $223.50 | $22.4K | Form 4 |
| 2026-05-29 | BIENAIME JEAN JACQUES | Director | Open-market purchase | 200 | $222.30 | $44.5K | Form 4 |
| 2026-05-29 | BIENAIME JEAN JACQUES | Director | Open-market purchase | 200 | $223.76 | $44.8K | Form 4 |
| 2026-05-26 | BIENAIME JEAN JACQUES | Director | Open-market purchase | 200 | $239.37 | $47.9K | Form 4 |
| 2026-05-26 | BIENAIME JEAN JACQUES | Director | Open-market purchase | 200 | $236.24 | $47.2K | Form 4 |
| 2026-05-11 | JENSEN FLEMMING STEEN | Officer (See Remarks) | Open-market sale | 19,460 | $238.49 | $4.64M | Form 4 |
| 2026-04-14 | BIENAIME JEAN JACQUES | Director | Grant / award / vesting (derivative) | 9,160 | — | — | Form 4 |
| 2026-04-14 | BIENAIME JEAN JACQUES | Director | Disposition to the issuer (derivative) | 9,160 | — | — | Form 4 |
Ask the chat about ASND's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Ascendis Pharma (ASND).
Last updated 2026-09-08 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.